Welcome to our dedicated page for Sonnet Biotherapeutc Hldng SEC filings (Ticker: SONN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Sonnet BioTherapeutics Holdings, Inc. (historically trading under the ticker SONN). These documents record the company’s regulatory history as an oncology-focused biotechnology issuer and capture key events such as shareholder meetings, financing transactions, and the business combination with Hyperliquid Strategies Inc. that resulted in Sonnet becoming a wholly owned subsidiary of a new Nasdaq-listed entity.
Investors can use Sonnet’s Form 8‑K filings to track material developments. Recent 8‑Ks describe, among other items, the entry into a Business Combination Agreement with Rorschach I LLC and Hyperliquid Strategies Inc., the structure of the mergers that formed Hyperliquid Strategies Inc. as the parent company, and subsequent confirmations of Nasdaq listing compliance. Other 8‑Ks detail private placements of preferred stock and warrants, the issuance of convertible notes and associated warrants, and employment agreements and compensation arrangements for senior executives.
The company’s Definitive Proxy Statement on Schedule 14A outlines matters submitted to stockholders, including the election of directors, advisory votes on executive compensation, auditor ratification, and the logistics of virtual annual meetings. These materials also provide information about board composition, governance practices, and the proposals that required shareholder approval in connection with major transactions.
Through Sonnet’s periodic and current reports, readers can understand how the company structured the business combination with Hyperliquid Strategies Inc., including the planned issuance of Pubco (Hyperliquid Strategies Inc.) common stock, contingent value rights (CVRs) related to Sonnet’s biotech assets, and the anticipated ownership percentages of legacy Sonnet stockholders versus new investors. Filings also describe responses to Nasdaq stockholders’ equity requirements and the company’s efforts to maintain listing standards prior to the corporate reorganization.
On Stock Titan, these filings are complemented by AI-powered tools that summarize lengthy documents and highlight key terms, helping users interpret complex sections of 8‑Ks, proxy statements, and related agreements. Real-time updates from the SEC’s EDGAR system allow users to see new filings as they are posted, while structured views of items such as financing terms and governance proposals make it easier to compare disclosures across documents. For historical research on SONN and its transition into a subsidiary of Hyperliquid Strategies Inc. (whose stock is expected to trade under the ticker PURR), this page serves as a central reference for the company’s official regulatory record.
Sonnet BioTherapeutics Holdings, Inc. provides an annual update as a clinical-stage biotech focused on oncology and neuropathy, built around its proprietary FHAB albumin-binding platform to extend cytokine half-life and target tumors.
The lead program, SON-1010 (IL12-FHAB), has dosed 103 patients and healthy volunteers across three Phase 1 studies, showing prolonged interferon gamma responses, manageable safety with no dose-limiting toxicities, and early clinical benefit in advanced solid tumors and platinum-resistant ovarian cancer, including partial and complete responses at the highest doses and ongoing expansion cohorts.
SON-080, a low-dose IL-6 for chemotherapy-induced and diabetic peripheral neuropathy, showed tolerability and symptom-improvement signals in a small Phase 1b group and is now licensed to Alkem in India with a $1.0 million upfront payment plus potential milestones and low double-digit royalties, while SON-1210, a bifunctional IL-12/IL-15 construct, has completed IND-enabling toxicology and is planned for an investigator-initiated Phase 1/2a study in metastatic pancreatic cancer. The company highlights a history of operating losses and a need for significant additional capital, with aggregate non-affiliate common equity valued at $4,150,174 on March 31, 2025, based on a $1.34 share price.
Sonnet BioTherapeutics Holdings, Inc. filed a post-effective amendment to multiple Form S-3 registration statements to end all registered securities offerings following its merger into Hyperliquid Strategies Inc. On December 2, 2025, through a series of mergers, Sonnet became a direct wholly owned subsidiary of Hyperliquid Strategies, and Rorschach I LLC became its affiliate subsidiary.
The amendment terminates the effectiveness of the listed Form S-3 registration statements and removes from registration all securities that had been registered but remained unsold, including offerings such as up to 5,770,14 shares of common stock issuable upon exercise of outstanding warrants and a mixed shelf for up to $100 million of various securities. After this action, Sonnet no longer has securities registered for sale under these S-3 registration statements.
Sonnet BioTherapeutics Holdings, Inc. has filed a post-effective amendment to multiple Form S-3 registration statements to terminate their effectiveness and deregister all securities that had been registered but remain unsold. This action follows completion of a business combination on December 2, 2025, in which Sonnet became a direct wholly owned subsidiary of Hyperliquid Strategies Inc. through successive mergers involving Rorschach I LLC and two merger subsidiaries.
With this amendment, Sonnet confirms that all offerings under these S-3 registration statements, including a shelf that had allowed issuance of up to $100 million of various securities, have been terminated, and there are no remaining securities registered by Sonnet under these statements.
Sonnet BioTherapeutics Holdings, Inc. filed a post-effective amendment to its Form S-3 registration statements to deregister all securities that remain unsold under those registrations. The company has terminated all offerings of securities pursuant to these Form S-3 registration statements.
This step follows a business combination completed on December 2, 2025, in which Rorschach Merger Sub merged into Rorschach I LLC and, immediately afterward, Company Merger Sub merged into Sonnet, leaving Sonnet as a direct wholly owned subsidiary of Hyperliquid Strategies Inc. After this amendment, there will be no remaining securities registered by Sonnet under the affected Form S-3 registration statements.
Sonnet BioTherapeutics Holdings, Inc. filed a post-effective amendment to multiple Form S-1 registration statements. The move follows a December 2, 2025 business combination in which Sonnet became a direct wholly owned subsidiary of Hyperliquid Strategies Inc. In connection with that merger, Sonnet has terminated all offerings under these S-1s and, consistent with its prior undertakings, is removing from registration all securities that remained unsold. After giving effect to this amendment, there will be no securities left registered by Sonnet under the affected Form S-1 registration statements.
Sonnet BioTherapeutics Holdings, Inc. director Susan Dexter reported a change in her holdings tied to the company’s merger with Hyperliquid Strategies Inc. On December 2, 2025, 9,643 shares of Sonnet common stock were disposed of, leaving her with zero Sonnet shares held directly after the transaction.
The transaction occurred in connection with a Business Combination Agreement among Sonnet, Rorschach I LLC, Hyperliquid Strategies Inc., and related merger subsidiaries. In this deal, Rorschach became a wholly owned subsidiary of Hyperliquid Strategies Inc., and Sonnet was merged into a separate subsidiary and survived as a direct wholly owned subsidiary of Hyperliquid Strategies Inc.
The filing notes that 8,000 restricted stock units granted on July 11, 2025 and 1,643 previously vested restricted stock units were included in these holdings. At the effective time of the merger, each Sonnet restricted stock unit was exchanged for one-fifth of a share of Hyperliquid Strategies Inc. common stock and one contingent value right, with all amounts reflecting Sonnet’s prior reverse stock splits.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has adjourned its special stockholder meeting to give investors more time to vote on the proposed business combination with Hyperliquid Strategies Inc. (HSI) and Rorschach I LLC. The company states that more than 95% of the shares already voted on the transaction have supported the deal, but approval still requires a majority of all outstanding shares.
The special meeting is rescheduled for 9:00 a.m. Eastern Time on December 2, 2025, via a virtual link, with the board unanimously recommending that stockholders vote in favor of all proposals. HSI’s shares have been approved for listing by Nasdaq upon completion of the transaction, while Sonnet highlights its oncology-focused FHAB platform as the core of its biologic drug development strategy.
Sonnet BioTherapeutics Holdings, Inc. reported that it has adjourned its special stockholder meeting to 9:00 a.m. Eastern Time on December 2, 2025. The meeting was postponed to give investors more time to vote on the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC, along with other related proposals. Stockholders who were of record on October 20, 2025 remain entitled to vote and may attend the reconvened virtual meeting via the provided web address. The company also highlighted that additional details about the transaction are available in the previously mailed proxy statement/prospectus and other SEC filings.